Hanmi Pharm's cefixime won COS

Published: 2003-09-22 06:58:00

Updated: 2003-09-22 06:58:00

Hanmi Pharm said that it has acquired from the European Pharmacopoeia Commission the certification of suitability (COS) on cefixime, antibiotic bulk material, for the third time following ceftriaxone and cefotaxime, adding that its COS acquisitions reflect the largest number among domestic pharma...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK